FIELD: molecular biology and biotechnology.
SUBSTANCE: invention relates to the compositions and methods of producing transduced (transfected) cells, where the said cells optionally produce an adeno-associated viral vector (rAAV). Cells transduced/transfected at high efficiency with plasmids containing (i) nucleic acids encoding AAV packaging proteins and/or nucleic acids encoding helper proteins; and (ii) a transgene that encodes a protein or is transcribed into a transcript of interest can produce a large amount of the recombinant rAAV vector.
EFFECT: obtaining amplifier agents to increase cell transfection and/or rAAV vector production.
60 cl, 8 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| COLUMN-BASED METHODS FOR CLEANING VECTOR BASED ON AAV | 2018 |
|
RU2772876C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
| RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, SUITABLE IN TREATMENT OF OSTEOARTHRITIS AND SIMILAR JOINT DISEASES IN MAMMALS | 2017 |
|
RU2771490C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
| FUSED PROTEIN OF SHORT FORM OF CONE VIABILITY FACTOR OBTAINED FROM RODS, AND HYDROPHILIC PEPTIDE | 2017 |
|
RU2773368C2 |
| ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
